Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
13 studies found for:    matulonis
Show Display Options
Rank Status Study
1 Recruiting Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Pembrolizumab;   Drug: Pegylated Liposomal Doxorubicin (PLD)
2 Completed
Has Results
Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: Bevacizumab;   Drug: Cyclophosphamide
3 Terminated
Has Results
Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer;   Mixed Tumor, Mesodermal
Interventions: Drug: Paclitaxel;   Drug: Carboplatin
4 Completed Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: Carboplatin;   Drug: Pemetrexed
5 Withdrawn Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: Olaparib
6 Terminated GSK1120212+GSK2141795 for Cervical Cancer
Condition: Cervical Cancer
Interventions: Drug: GSK1120212 (trametinib);   Drug: GSK2141795
7 Terminated
Has Results
Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Vorinostat;   Drug: Carboplatin;   Drug: Gemcitabine
8 Active, not recruiting Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Conditions: Ovarian Cancer;   Breast Cancer
Interventions: Drug: BKM120 and Olaparib;   Drug: BYL719 and Olaparib
9 Active, not recruiting Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
10 Completed
Has Results
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Ovarian Epithelial Cancer;   Stage I Ovarian Epithelial Cancer;   Stage II Ovarian Epithelial Cancer
Intervention: Drug: cediranib maleate
11 Recruiting Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer
Conditions: Epithelial Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Drug: entinostat;   Drug: avelumab;   Drug: Placebo
12 Completed A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Condition: Platinum Sensitive Ovarian Cancer
Interventions: Drug: Active comparator: Niraparib;   Drug: placebo
13 Recruiting Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Interventions: Drug: Part A - VS-6063;   Drug: Part A - Avelumab

Study has passed its completion date and status has not been verified in more than two years.